Research Article ISSN 2639-8451

Addiction Research

A Neurobiological Disease Model of Addiction

Edward Ruvins, DDS, MS, MBA, MSF, MSAC, LAC[1]*, Katie Brydon LCSW, LAC, MAC, EMDR-c[2], Susanna Kayserman, DDS[3], Mark Stein, DDS, MD[4] and Chloe V Ruvins[5]

[1]*Founder of Genesis Behavioral Health, Lighthouse Recovery and Optimum Consulting Group, USA.*

[2]*Co-founder of Genesis Behavioral Health, Founder of Road to Me Recovery, Colorado, USA.*

[3]*Assistant Professor, Oral & Maxillofacial Surgery, New York University, USA.*

[4]*Member of the American Dental Association and the Academy of Osseointegration, Illinois, USA.*

[5]*Researcher, University of Miami, Florida, USA.*

***Correspondence:**
Edward Ruvins, Founder of Genesis Behavioral Health, Lighthouse Recovery and Optimum Consulting Group, USA.

Received: 03 Aug 2025; **Accepted:** 05 Sep 2025; **Published:** 14 Sep 2025

Citation: Edward Ruvins, Katie G Brydon, Susanna Kayserman, et al. A Neurobiological Disease Model of Addiction. Addict Res. 2025; 9(3): 1-4.

ABSTRACT

Addiction affects millions of individuals and imposes profound medical, social, and economic costs on today's society. Furthermore, the emergence of addiction as a global phenomenon presented one of the most pressing global health challenges known to humans. Progressively, addiction is no longer conceptualized as a moral weakness or as a failure of willpower, but rather as a chronic, relapsing neurobiological ailment with well-defined alterations in brain structure and function.

Advances in neuroscientific research have demonstrated that repeated exposure to addictive substances produces maladaptive changes in neural circuits controlling reward circuits, executive control, motivation, and stress reactivity. While prefrontal cortex impairments weaken inhibitory control and decision-making, dysregulation of the mesolimbic dopamine system reinforces compulsive drug-seeking. Simultaneous hyperactivation of the amygdala and hypothalamic-pituitary-adrenal (HPA) axis heightens stress sensitivity and relapse vulnerability, further perpetuating the cycle of use. Evidence from neuroimaging studies, genetic research, and animal models consistently supports this model of the disease framework, highlighting addiction's inherited components and newly formed neuroplastic variations.

This review synthesizes the current view of core neurobiological mechanisms of addiction and examines the empirical evidence supporting the disease model. Additionally, this article addresses outlining implications for treatment, policy, and future research.

Keywords
Neuroplastics, Neurobiological Disease, Addiction, Drugs.

Introduction

Addiction is a complex and devastating condition, characterized by compulsive drug use despite adverse consequences, high relapse rates, and chronicity. Addiction research and medical science increasingly regard addiction as a brain-based disease with identifiable neurobiological mechanisms [1]. More comprehensive and compassionate understanding of addiction emerged through integrating neuroscience and closer examination of psychosocial frameworks guiding the research and development of effective clinical interventions and contributing to informed public policy development addressing addiction as a societal problem.

Addiction is best understood as a neurobiological disease of the brain that fundamentally alters reward, stress, and executive systems. While not excluding social and psychological factors, the neurobiological model offers a robust framework for research, treatment, and policy reform. Ultimately, acknowledging addiction as a brain disorder fosters compassion, reduces stigma, and aligns societal responses with science [2].

Historical Emergence of a Disease Model

Historical conceptions of addiction emphasized inadequate morality, personal choice, and social deviance. While recognition of addiction as a medical condition was considered unorthodox by many, the mid-20th century marked a transition toward medical and psychiatric perspectives, recognizing substance use disorders as conditions requiring treatment rather than punishment. Further integration of neuroscience and examination of psychological elements of the disease strengthened the argument for a disease model by identifying specific neural circuits disrupted by chronic drug exposure [3].

Despite substantial empirical grounding, the neurobiological disease model has faced criticism for oversimplifying addiction and minimizing the role of choice, psychosocial influences, and structural determinants such as poverty and trauma. Satel and Lilienfeld critiqued the neurobiological disease model for neglecting choice, psychosocial factors, and social context [4]. Hammer et al. reviewed major critiques of the brain disease framework and emphasized social and structural determinants of addiction development [5]. Hall and Carter provided a balanced analysis and acknowledged oversimplification of the orthodox view of the addiction but also recognized how the new, medically based model of addiction, reduced stigma and encouraged evidence-based treatment [6].

Conversely, Volkow and Koob defended the brain disease model of addiction against criticisms, citing the consistency of neurobiological evidence of synaptic and circuitry changes [7]. These theoretical concepts effectively lead to development of medications like naloxone and varenicline, countering claims that it lacks evidence or has failed to produce effective treatments and assert that the neurobiological disease model of the addiction as a disease is empirically sound and highlights how understanding addiction's biological underpinnings helps explain compulsive behavior, aids in developing new treatments, and reduces stigma by reframing addiction as a medical condition.

Neurobiology of Addiction

Core Principles of the Neurobiological Disease Model

The neurobiological model of addiction is anchored in three main principles:

1. Addiction is a chronic brain disease involving long-lasting alterations in neural circuitry.
2. Neuroadaptations in reward and control systems drive compulsive drug use and impaired self-regulation.
3. Relapse vulnerability is explained by enduring changes in stress and motivation systems, which persist long after detoxification.

Reward Circuitry and Dopamine Dysregulation

The mesolimbic dopamine pathway, a central neurocircuit in reward processing, connects the ventral tegmental area (VTA) to the nucleus accumbens (NAc). The mesolimbic dopamine pathway has additional connections to the amygdala, hippocampus, and prefrontal cortex, playing a pivotal role in reinforcing behaviors essential for survival, such as eating and reproduction, by linking environmental cues to reward and motivation. Most addictive substances amplify dopaminergic signaling, producing euphoria and reinforcing drug-taking behavior [8]. Psychostimulants like cocaine and amphetamines, opioids like heroin and morphine, alcohol, and nicotine all amplify dopaminergic signaling within this pathway, either by directly stimulating dopamine release, blocking its reuptake, or modulating upstream neurotransmitter systems [8]. The resulting cyclical dopamine surges produce euphoria and strengthen associative learning between drug use and environmental cues, further reinforcing drug-taking behavior.

Consequently, such repeated exposure causes the system to undergo profound neuroadaptations with further development of tolerance as dopamine receptors, particularly D2 receptors in the striatum, become downregulated, requiring escalating doses to achieve the same effect. Simultaneously, sensitization may occur when drug-associated cues elicit exaggerated dopaminergic responses, intensifying craving and compulsive seeking. Over time, the heightened levels of drug-related stimuli are paralleled by a diminished responsiveness to natural rewards such as food and pleasurable activities. Volkow et al. referred to this phenomenon as “the reward deficiency syndrome” [9]. These neuroadaptations shift motivational priorities toward substance use at the expense of natural adaptive behaviors to drug rewards, laying the neurobiological foundation for compulsive drug seeking and chronic relapse vulnerability [10].

Neuroadaptations and Synaptic Remodeling

Long-term potentiation (LTP) and long-term depression (LTD) within the nucleus accumbens (NAc) and prefrontal cortex (PFC) represent critical forms of synaptic plasticity that shape reward learning and behavioral regulation. Dysregulation of these mechanisms through repeated drug exposure disrupts the balance between excitatory and inhibitory signaling, thereby impairing the PFC's ability to exert top-down control over the NAc.

Moreover, chronic drug use induces maladaptive plasticity, particularly in glutamate and GABA transmission

Such maladaptive plastic changes shift neural circuits toward heightened drug salience while weakening the encoding of natural rewards and inhibitory control processes, ultimately reinforcing compulsive drug-seeking patterns and diminishing cognitive flexibility [11].

Prefrontal Cortex Dysfunction and Executive Impairment

The prefrontal cortex (PFC), a central hub for executive functions such as decision-making, inhibitory control, and the regulation of goal-directed behavior, is consistently compromised in individuals with substance use disorders. Structural neuroimaging studies demonstrate significant reductions in gray matter density and cortical thickness within key subregions, most notably the inferior frontal gyrus (IFG) and anterior cingulate cortex (ACC) areas critically involved in conflict monitoring, error detection, and top-down regulation of impulsive drives [12]. These structural abnormalities are paralleled by functional impairments, with task-

based fMRI consistently revealing hypoactivity of the PFC during inhibitory control tasks and hyper-responsiveness of subcortical reward circuits to drug cues [13]. This imbalance between cortical regulation and subcortical reward salience undermines self-regulatory capacity, manifesting clinically as impaired inhibitory control, heightened impulsivity, and maladaptive decision-making. In turn, these deficits leave addicted individuals highly vulnerable to craving-driven relapses, as the weakened PFC is unable to adequately suppress drug-seeking impulses in the face of conditioned cues and stressors [11].

Stress Systems and the Hypothalamic-Pituitary-Adrenal Axis

Addiction is increasingly recognized not only as a disorder of reward and executive control but also as a disorder of stress regulation. The hypothalamic-pituitary-adrenal (HPA) axis is a system normally responsible for maintaining homeostasis during stress. Dysregulation of the HPA plays a central role in perpetuating compulsive drug use [11]. Chronic substance exposure produces maladaptive neuroadaptations within corticotropin-releasing factor (CRF) signaling pathways, leading to heightened HPA activity and hyper-responsivity to stressors [14]. Concurrently, the amygdala, a key node in emotional processing and stress reactivity, exhibits hyperactivity in addicted individuals, which amplifies adverse effects and craving intensity [15]. This dysregulated stress circuitry fuels a vicious cycle: stress precipitates craving, craving increases vulnerability to relapse, and relapse further sensitizes stress pathways, making sustained abstinence increasingly difficult to maintain [11,16].

Addiction as a Chronic Relapsing Disorder - Clinical Dynamics

Addiction demonstrates many of the defining characteristics of a chronic, relapsing medical disorder. The clinical trajectory typically follows a course marked by escalation of use, periods of abstinence or remission, recurrent relapse, and, in some cases, progressive functional decline [17]. Longitudinal studies indicate that rates of relapse in substance use disorders are comparable to those observed in other chronic illnesses such as diabetes, hypertension, and asthma, underscoring the importance of long-term disease management rather than acute, episodic care [18].

From a therapeutic perspective, the responsiveness of addiction to pharmacological treatment provides further support for its classification as a medical condition. Medications such as **methadone** and **buprenorphine** (opioid agonist therapies) stabilize neurobiological dysregulation within the opioid system, reduce craving and withdrawal, and are associated with improved treatment retention and decreased mortality [19,20].

Naltrexone, an opioid receptor antagonist, provides another effective option by blocking the euphoric effects of opioids and alcohol, thereby supporting abstinence in motivated patients [21]. Similarly, agents such as **acamprosate** and **disulfiram** have demonstrated efficacy in alcohol use disorder, further reinforcing the principle that targeted pharmacotherapies can modulate specific neurochemical pathways implicated in addiction [22].

The effectiveness of these medications, alongside behavioral interventions, illustrates that substance use disorders respond to treatment in ways consistent with other chronic medical conditions. Moreover, evidence demonstrates that pharmacotherapy, when delivered in combination with psychosocial support, not only reduces drug use but also improves social functioning, decreases risks of infectious disease transmission, and lowers overall health care costs [23].

Combined with other empirical evidence presented in modern addiction research literature, these findings underscore the chronic yet treatable nature of addiction and highlight the necessity of sustained, comprehensive management strategies.

Conclusion

Despite ongoing debate about the conceptualization of addiction as a brain disease, the development of modern clinical opinions has profoundly influenced both scientific inquiry and clinical practice. The brain-disease model has legitimized the neurobiological underpinnings of addiction, reducing moralistic interpretations and stigma by emphasizing that compulsive drug use arises from pathological changes in brain circuits rather than from a lack of willpower [24].

This insight into addiction has also transformed treatment approaches, providing the rationale for developing pharmacotherapies (e.g., naltrexone, buprenorphine, acamprosate) that target specific neurochemical systems, while simultaneously supporting the use of evidence-based behavioral interventions, such as cognitive-behavioral therapy (CBT), contingency management, and mindfulness-based relapse prevention. At the public health level, the brain-disease perspective has underpinned harm reduction initiatives, including medication-assisted treatment (MAT), needle-exchange programs, and expanded access to naloxone, shifting the focus from punishment to treatment and care. Thus, even while critiques remain about potential over-medicalization or neglect of psychosocial factors, the neurobiological framework has played a critical role in advancing a more compassionate, evidence-driven, and integrative response to addiction.

References

1. Volkow ND, Koob GF. Brain disease model of addiction: why is it so controversial? Lancet Psychiatry. 2015.
2. OpenAI. ChatGPT (March 14 version) [Large language model]. https://chat.openai.com/. 2025.
3. Leshner AI. Addiction is a brain disease, and it matters. Science. 1997.
4. Satel S, Lilienfeld SO. Addiction and the brain-disease fallacy. Front Psychiatry. 2014; 5: 120.
5. Hammer R, Dingel M, Ostergren J, et al. Addiction: Current Criticism of the Brain Disease Paradigm. AJOB Neurosci. 2013; 4: 27-32.
6. Hall W, Carter A, Forlini C. The brain disease model of addiction: is it supported by the evidence and has it delivered on its promises? Lancet Psychiatry. 2015; 2: 105-110.

7. Volkow ND, Koob GF. Brain disease model of addiction: why is it so controversial? Lancet Psychiatry. 2015.
8. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci. 2005.
9. Volkow ND, Wang GJ, Fowler JS, et al. Addiction: Decreased reward sensitivity and increased expectation sensitivity conspire to overwhelm the brain's control circuit. BioEssays. 2010; 32: 748-755.
10. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016; 3: 760-773.
11. Kauer JA, Malenka RC. Synaptic plasticity and addiction. Nature Reviews Neuroscience. 2007.
12. Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci. 2011; 12: 652-669.
13. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016; 3: 760-773.
14. Everitt BJ, Robbins TW. Drug addiction: updating actions to habits to compulsions ten years on. Annu Rev Psychol. 2016; 67: 23-50.
15. Koob GF. A role for brain stress systems in addiction. Neuron. 2008; 59: 11-34.
16. Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci. 2008; 1141: 105-130.
17. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016; 3: 760-773.
18. Volkow ND, Koob GF, McLellan AT, et al. Neurobiological advances from the brain disease model of addiction. N Engl J Med. 2016; 374: 363-371.
19. McLellan AT, Lewis DC, O'Brien CP, et al. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA. 2000; 284: 1689-1695.
20. Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014; CD002207.
21. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ. 2017; 357: j1550.
22. Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: A review. JAMA. 2018; 320: 815-824.
23. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study. JAMA. 2006; 295: 2003-2017.
24. Volkow ND, Koob GF, McLellan AT, et al. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016; 374: 363-371.